We further investigated the role of the finger (F) and the kringle-2 (K2) domains of tissue-type plasminogen activator (t-PA) in fibrin-stimulated plasminogen activation. To that end, the action of purified (wt) t-PA or of variants lacking F (del.F) or K2 (del.K2) was assessed either in a static, human whole blood clot-lysis system or in whole blood thrombi generated in the ''Chandler loop''. In both clot-lysis systems, significant differences were observed for the initiation of thrombolysis with equimolar concentrations of the t-PA variants. A relatively minor ''lag phase'' occurred in thrombolysis mediated by wt t-PA, whereas a 6.4-fold and 1.6-fold extension is found for del.F and del.K2, respectively. We observed identical lag-times, ch...
Despite its affinity for fibrin, tissue plasminogen activator (t-PA) administration causes systemic ...
Plasminogen activator inhibitor 1 (PAI-1) is a glycoprotein that controls the activity of the key en...
Development of appropriate clinical dose regimens of individual plasminogen activators such as tissu...
Plasminogen activation is catalyzed both by tissue-type- (t-PA) and by urokinase-type plasminogen ac...
The dissolution of blood clots by plasmin is normally initiated in vivo by the activation of plasmin...
The fibrin clot is gelatinous matter formed upon injury to stop blood loss and is later destroyed by...
Background. We investigated the effect of inhibition of plasminogen activator inhibitor-1 (PAI-1) ac...
Myocardial infarction (MI) and ischemic stroke (IS) are caused by blood clots blocking arteries and ...
In this thesis, we investigated the role of the fibrinolytic system in arterial and venous thrombosi...
Plasminogen activator inhibitor 1 (PAI-1) is the main physiological inhibitor of tissue-type plasmin...
Sixty-four variants of human tissue-type plasminogen activator (tPA) were produced using recombinant...
To describe the role of the lysyl binding site in the interaction of tissue-type plasminogen activat...
A well characterized model of an intact and a degraded surface of fibrin that represents the states ...
The fibrin-specific thrombolyticum tissue-type plasminogen activator (t-PA) has proven to be a poten...
activation Mammalian plasma contains an enzymatic system capable of dissolving the fibrin in blood c...
Despite its affinity for fibrin, tissue plasminogen activator (t-PA) administration causes systemic ...
Plasminogen activator inhibitor 1 (PAI-1) is a glycoprotein that controls the activity of the key en...
Development of appropriate clinical dose regimens of individual plasminogen activators such as tissu...
Plasminogen activation is catalyzed both by tissue-type- (t-PA) and by urokinase-type plasminogen ac...
The dissolution of blood clots by plasmin is normally initiated in vivo by the activation of plasmin...
The fibrin clot is gelatinous matter formed upon injury to stop blood loss and is later destroyed by...
Background. We investigated the effect of inhibition of plasminogen activator inhibitor-1 (PAI-1) ac...
Myocardial infarction (MI) and ischemic stroke (IS) are caused by blood clots blocking arteries and ...
In this thesis, we investigated the role of the fibrinolytic system in arterial and venous thrombosi...
Plasminogen activator inhibitor 1 (PAI-1) is the main physiological inhibitor of tissue-type plasmin...
Sixty-four variants of human tissue-type plasminogen activator (tPA) were produced using recombinant...
To describe the role of the lysyl binding site in the interaction of tissue-type plasminogen activat...
A well characterized model of an intact and a degraded surface of fibrin that represents the states ...
The fibrin-specific thrombolyticum tissue-type plasminogen activator (t-PA) has proven to be a poten...
activation Mammalian plasma contains an enzymatic system capable of dissolving the fibrin in blood c...
Despite its affinity for fibrin, tissue plasminogen activator (t-PA) administration causes systemic ...
Plasminogen activator inhibitor 1 (PAI-1) is a glycoprotein that controls the activity of the key en...
Development of appropriate clinical dose regimens of individual plasminogen activators such as tissu...